UZH-Logo

Maintenance Infos

Brentuximab as a treatment for CD30+ Mycosis Fungoides and Sézary Syndrome


Mehra, Tarun; Ikenberg, Kristian; Moos, Rudolf Maria; Benz, Rudolf; Nair, Gayathri; Schanz, Urs; Haralambieva, Eugenia; Hoetzenecker, Wolfram; Dummer, Reinhard; French, Lars Einar; Guenova, Emmanuella; Cozzio, Antonio (2015). Brentuximab as a treatment for CD30+ Mycosis Fungoides and Sézary Syndrome. JAMA Dermatology, 151(1):73-77.

Abstract

Importance: The prognosis of advanced cutaneous T-cell lymphoma (CTCL), including Sézary syndrome and mycosis fungoides (MF), is poor. So far, no curative option apart from allogeneic stem cell transplantation is available. Large cell transformation often hallmarks cases with a more aggressive clinical course, and large tumor cells may express CD30. Recently, brentuximab vedotin, a conjugate of an anti-CD30 antibody and monomethylauristatin E, which inhibits the polymerization of microtubuli, has produced promising results in phase 2 trials in CD30+ Hodgkin lymphoma and anaplastic large cell lymphoma.
Observations: We describe 4 patients with advanced CTCL, 3 with MF and 1 with Sézary syndrome, who were treated with brentuximab. All patients had received multiple previous systemic therapies. In 2 cases of MF, a remission enabling subsequent allogeneic stem cell transplantation was achieved.
Conclusions and Relevance: rentuximab is a well-tolerated, promising new treatment option for advanced CTCL that can be integrated in an allogeneic stem cell transplantation plan by selectively depleting malignant CD30+ cutaneous lymphoma cells.

Importance: The prognosis of advanced cutaneous T-cell lymphoma (CTCL), including Sézary syndrome and mycosis fungoides (MF), is poor. So far, no curative option apart from allogeneic stem cell transplantation is available. Large cell transformation often hallmarks cases with a more aggressive clinical course, and large tumor cells may express CD30. Recently, brentuximab vedotin, a conjugate of an anti-CD30 antibody and monomethylauristatin E, which inhibits the polymerization of microtubuli, has produced promising results in phase 2 trials in CD30+ Hodgkin lymphoma and anaplastic large cell lymphoma.
Observations: We describe 4 patients with advanced CTCL, 3 with MF and 1 with Sézary syndrome, who were treated with brentuximab. All patients had received multiple previous systemic therapies. In 2 cases of MF, a remission enabling subsequent allogeneic stem cell transplantation was achieved.
Conclusions and Relevance: rentuximab is a well-tolerated, promising new treatment option for advanced CTCL that can be integrated in an allogeneic stem cell transplantation plan by selectively depleting malignant CD30+ cutaneous lymphoma cells.

Citations

10 citations in Web of Science®
10 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

0 downloads since deposited on 30 Oct 2014
0 downloads since 12 months

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Hematology
04 Faculty of Medicine > University Hospital Zurich > Institute of Surgical Pathology
04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:1 January 2015
Deposited On:30 Oct 2014 13:19
Last Modified:05 Apr 2016 18:26
Publisher:American Medical Association (AMA)
ISSN:2168-6068
Publisher DOI:https://doi.org/10.1001/jamadermatol.2014.1629
PubMed ID:25317818
Permanent URL: https://doi.org/10.5167/uzh-99890

Download

[img]
Content: Published Version
Filetype: PDF - Registered users only
Size: 428kB
View at publisher

TrendTerms

TrendTerms displays relevant terms of the abstract of this publication and related documents on a map. The terms and their relations were extracted from ZORA using word statistics. Their timelines are taken from ZORA as well. The bubble size of a term is proportional to the number of documents where the term occurs. Red, orange, yellow and green colors are used for terms that occur in the current document; red indicates high interlinkedness of a term with other terms, orange, yellow and green decreasing interlinkedness. Blue is used for terms that have a relation with the terms in this document, but occur in other documents.
You can navigate and zoom the map. Mouse-hovering a term displays its timeline, clicking it yields the associated documents.

Author Collaborations